Ginger, a cousin spice of super anti-cancer substance turmeric, is known for its ability to shrink tumors. Astoundingly, it is even more effective than many cancer drugs, which have been shown to be completely ineffective and actually accelerate the death of cancer patients. Commonly consumed across the world in small doses among food and beverage products, the medicinal properties of ginger far surpass even advanced pharmaceutical inventions.
The subject of one study based out of Georgia State University, whole ginger extract was revealed to shrink prostate tumor size by a whopping 56% in mice.
The anticancer properties were observed in addition to ginger’s role in reducing inflammation as well as being a rich source of life-enhancing antioxidants.
But what about cancer drugs? Could this simple spice really topple the advanced pharmaceuticals that are often touted as the ‘only option’ for cancer patients by medical doctors?
It turns out that cancer drugs are not only severely ineffective at permanently shrinking tumors, but they actually make tumors larger and kill the patient more quickly.
More specifically, the tumors have been found to ‘metasize’, meaning they come back bigger and more stronger than their original size. What’s more, the ‘metasizing’ was found to be very aggressive. According to scientists Beth Israel Deaconess Medical Center in Boston, the premium priced drugs were little more than death sentences for many patients.
“Whatever manipulations we’re doing to tumors can inadvertently do something to increase the tumor numbers to become more metastatic, which is what kills patients at the end of the day,” said study author Dr. Raghu Kalluri.
These are the very drugs considered to be the scientifically proven solution by mainstream health officials.
Meanwhile, ginger presents virtually no side effects and has been used as a food product by many cultures for countless centuries. Instead of creating super tumors, whole ginger extract was shown to exert significant growth-inhibiting and death-inductory effects in a spectrum of prostate cancer cells.
